These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 31469910)

  • 1. New drugs approved for acute myeloid leukaemia in 2018.
    Kucukyurt S; Eskazan AE
    Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory
    Short NJ; Daver N; Dinardo CD; Kadia T; Nasr LF; Macaron W; Yilmaz M; Borthakur G; Montalban-Bravo G; Garcia-Manero G; Issa GC; Chien KS; Jabbour E; Nasnas C; Huang X; Qiao W; Matthews J; Stojanik CJ; Patel KP; Abramova R; Thankachan J; Konopleva M; Kantarjian H; Ravandi F
    J Clin Oncol; 2024 May; 42(13):1499-1508. PubMed ID: 38277619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venetoclax-based therapies for acute myeloid leukemia.
    Guerra VA; DiNardo C; Konopleva M
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New therapeutic agents for acute myeloid leukemia].
    Hosono N
    Rinsho Ketsueki; 2019; 60(9):1108-1119. PubMed ID: 31597834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What to use to treat AML: the role of emerging therapies.
    Thol F
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
    Griffiths EA; Carraway HE; Chandhok NS; Prebet T
    Leuk Res; 2020 Apr; 91():106339. PubMed ID: 32146154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drugs creating new challenges in acute myeloid leukemia.
    Tiong IS; Wei AH
    Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How I treat acute myeloid leukemia in the era of new drugs.
    DiNardo CD; Wei AH
    Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.
    Zucenka A; Maneikis K; Pugaciute B; Ringeleviciute U; Dapkeviciute A; Davainis L; Daukelaite G; Burzdikaite P; Staras V; Griskevicius L
    Ann Hematol; 2021 May; 100(5):1195-1202. PubMed ID: 33661333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AML: New Drugs but New Challenges.
    Burnett A; Stone R
    Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):341-350. PubMed ID: 32151586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3
    Fu Q; Wang Y; Liu H; Gao H; Sun W; Jiang Q; Jiang H; Liu K; Huang X; Tang F
    Leuk Res; 2024 Oct; 145():107564. PubMed ID: 39180903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
    Naoe T
    Nagoya J Med Sci; 2020 May; 82(2):151-160. PubMed ID: 32581396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
    Richardson DR; Green SD; Foster MC; Zeidner JF
    Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gilteritinib or Chemotherapy for Relapsed or Refractory
    Perl AE; Martinelli G; Cortes JE; Neubauer A; Berman E; Paolini S; Montesinos P; Baer MR; Larson RA; Ustun C; Fabbiano F; Erba HP; Di Stasi A; Stuart R; Olin R; Kasner M; Ciceri F; Chou WC; Podoltsev N; Recher C; Yokoyama H; Hosono N; Yoon SS; Lee JH; Pardee T; Fathi AT; Liu C; Hasabou N; Liu X; Bahceci E; Levis MJ
    N Engl J Med; 2019 Oct; 381(18):1728-1740. PubMed ID: 31665578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
    Zucenka A; Griskevicius L
    Br J Haematol; 2024 Apr; 204(4):1227-1231. PubMed ID: 38291741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [European approvals: Glasdegib for Acute myeloid leukemia].
    Barrière S; Gastaud L
    Bull Cancer; 2020 Dec; 107(12):1206-1207. PubMed ID: 33070952
    [No Abstract]   [Full Text] [Related]  

  • 19. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.
    Jonas BA; Pollyea DA
    Leukemia; 2019 Dec; 33(12):2795-2804. PubMed ID: 31628431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
    Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
    Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.